Coverage
-
November 14, 2018
A New Jersey federal judge Wednesday denied class certification in a suit claiming Ranbaxy Pharmaceuticals Inc. distributed pills that might have contained glass, saying there was not enough data to identify who got pills from the potentially affected batches.
7 other articles on this case.
View all »